The MLSC supports commercial scientific innovation by supporting early-stage and scaling companies. Ongoing programming and initiatives bridge funding gaps at the two highest need moments in a company’s lifecycle – seed-stage and scale up – to ensure a diverse, thriving environment of growing companies that attract a broader ecosystem of large companies:
Massachusetts Next Generation Initiative (MassNextGen) Competitive program to support women entrepreneurs in early-stage life sciences companies, by providing Capital, Access, and Recognition.
Regional Seed Fund Providing risk capital to promising life science companies in five communities with strong anchor research institutions outside Boston/Cambridge: Lowell, Worcester, Amherst, Springfield, and Pittsfield.
Massachusetts has the most robust and intelligent risk capital in the life sciences space. Firms here are not only making record deals in more established biotech and biopharma, but are also willing to take a real risk in bankrolling transformational new fields like microbiome and digital health.
Supply chain partners have strategic outposts in Massachusetts including global headquarters, R&D hubs, innovation centers, and venture arms. In addition, top CROs and CDMOs are investing in cutting-edge solutions for next-generation therapies. It is no coincidence that 22 of the top 30 medical device companies and 18 of the top 20 pharma companies are located in Massachusetts.
Companies and others can now propose clinical research partnerships with Massachusetts Academic Medical Centers through a single point of entry, with applications distributed to partnering officials at many of our world-renowned academic medical centers.